Overview

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

Status:
Completed

Trial end date:
2020-03-27

Target enrollment:

Participant gender:

Summary

CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Antibodies, Monoclonal
Nivolumab